[Proton pump inhibitor for ulcer therapy. Tolerance profile of lansoprazole].
Müller
P
P
Krankenhaus Salem, Heidelberg.
Fuchs
W
W
Peifer-Weiss
A
A
Simon
B
B
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000328:Adult; D016907:Adverse Drug Reaction Reporting Systems; D000368:Aged; D000897:Anti-Ulcer Agents / Q000009:adverse effects / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D004942:Esophagitis, Peptic / Q000188:drug therapy*; D005260:Female; D016481:Helicobacter Infections / Q000188:drug therapy*; D016480:Helicobacter pylori; D006801:Humans; D064747:Lansoprazole; D008297:Male; D008875:Middle Aged; D009853:Omeprazole / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D054328:Proton Pump Inhibitors
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000897:Anti-Ulcer Agents; D054328:Proton Pump Inhibitors; D064747:Lansoprazole; D009853:Omeprazole
Protonenpumpenhemmer zur Ulkustherapie. Verträglichkeitsprofil von Lansoprazol.